Clarivate
CLVTNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $2.39 Prior regular-session close from the quote source.
- $2.29–$2.46 Regular-session low and high so far today.
- 2.1M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 23 projected Projected for 2027-02-23 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $1.42–$3.87 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own CLVT if its proprietary data franchises stabilize before leverage and competition absorb the value.
CLVT price history
Loading recent earnings…
Investment thesis
What must happen next
Clarivate’s proprietary research, IP and life-sciences datasets remain embedded enough in customer workflows to stop the business from behaving like a melting database bundle.WeakeningMateriality: High
FY2025 annual GAAP revenue was still $2.455 billion, showing Clarivate retains a large customer revenue base despite pressure. If the embedded-data moat holds, revenue can stabilize and the turnaround has time to compound cash; if it fails, cost cuts only slow an economic decline.
Watch: Elsevier/RELX, LexisNexis, Questel, PatSnap or other workflow vendors win multi-year renewals by bundling comparable data with stronger analytics.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP revenue was still $2.455 billion, showing Clarivate retains a large customer revenue base despite pressure.
Open source ↗Clarivate’s content and software delivery model keeps incremental access low-cost enough that pricing pressure does not materially erode gross-profit economics.StrengtheningMateriality: High
FY2025 annual GAAP gross profit was $1.622 billion on $2.455 billion of revenue, an implied gross margin of about 66.0%. Resilient gross economics give management room to invest, simplify and deleverage; gross-margin erosion would signal the core data advantage is losing pricing power.
Watch: AI search and summarization tools make customers less willing to pay premium prices for proprietary database access.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP gross profit was $1.622 billion on $2.455 billion of revenue, an implied gross margin of about 66.0%.
Open source ↗Portfolio simplification and operating discipline can convert Clarivate’s high gross profit into sustainable GAAP operating income rather than letting amortization, impairments, restructuring and product sprawl consume the economics.HoldingMateriality: Medium
FY2025 annual GAAP operating income was positive $71.5 million, improving from a GAAP operating loss of $275.6 million in FY2024. The equity needs operating leverage, not just cash collections; if integration costs and impairments persist, the business may remain valuable to creditors but not to common shareholders.
Watch: Further goodwill or intangible impairments reveal that past acquisitions overpaid for assets with weaker demand than expected.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP operating income was positive $71.5 million, improving from a GAAP operating loss of $275.6 million in FY2024.
Open source ↗Recurring cash collections can fund liability reduction and product reinvestment internally, so equity value accrues to owners rather than being absorbed by creditors.StrengtheningMateriality: Medium
FY2025 annual GAAP operating cash flow was $628.5 million, following $646.6 million in FY2024. For a leveraged turnaround, cash flow is the bridge between a valuable data franchise and per-share value creation; if cash is consumed by debt service or restructuring, the common equity has little margin of safety.
Watch: Higher refinancing costs or near-term maturities redirect operating cash flow to creditors instead of product investment or debt reduction.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP operating cash flow was $628.5 million, following $646.6 million in FY2024.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Clarivate’s proprietary research, IP and life-sciences datasets remain embedded enough in customer workflows to stop the business from behaving like a melting database bundle. If the embedded-data moat holds, revenue can stabilize and the turnaround has time to compound cash; if it fails, cost cuts only slow an economic decline.
Clarivate’s content and software delivery model keeps incremental access low-cost enough that pricing pressure does not materially erode gross-profit economics. Resilient gross economics give management room to invest, simplify and deleverage; gross-margin erosion would signal the core data advantage is losing pricing power.
Portfolio simplification and operating discipline can convert Clarivate’s high gross profit into sustainable GAAP operating income rather than letting amortization, impairments, restructuring and product sprawl consume the economics. The equity needs operating leverage, not just cash collections; if integration costs and impairments persist, the business may remain valuable to creditors but not to common shareholders.
Recurring cash collections can fund liability reduction and product reinvestment internally, so equity value accrues to owners rather than being absorbed by creditors. For a leveraged turnaround, cash flow is the bridge between a valuable data franchise and per-share value creation; if cash is consumed by debt service or restructuring, the common equity has little margin of safety.
All standing thesis claims
Original report summary
its proprietary data franchises stabilize before leverage and competition absorb the value.
Bull case and bear case
Bull case and bear case for Clarivate
Where the evidence on Clarivate disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
Clarivate’s content and software delivery model keeps incremental access low-cost enough that pricing pressure does not materially erode gross-profit economics.
Portfolio simplification and operating discipline can convert Clarivate’s high gross profit into sustainable GAAP operating income rather than letting amortization, impairments, restructuring and product sprawl consume the economics.
Recurring cash collections can fund liability reduction and product reinvestment internally, so equity value accrues to owners rather than being absorbed by creditors.
Bear case: what the evidence questions
Clarivate’s proprietary research, IP and life-sciences datasets remain embedded enough in customer workflows to stop the business from behaving like a melting database bundle.
Thesis-Break Engine
What has broken in Clarivate’s thesis
Each break OptimistFi flagged on Clarivate, dated — with what has historically followed the same kind of break across the market, not a forecast for Clarivate.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Clarivate’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
Several kinds of break have stacked on Clarivate at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedCompleted an acquisition or disposition of assets.
Clarivate filed an SEC 8-K on 2026-10-06: Completed an acquisition or disposition of assets. It is a dated development that tests the current thesis.
- MixedOther material event.
Clarivate filed an SEC 8-K on 2026-09-24: Other material event. It is a dated development that tests the current thesis.
- MixedOther material event.
Clarivate filed an SEC 8-K on 2026-09-23: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Elsevier/RELX, LexisNexis, Questel, PatSnap or other workflow vendors win multi-year renewals by bundling comparable data with stronger analytics.
- AI search and summarization tools make customers less willing to pay premium prices for proprietary database access.
- Further goodwill or intangible impairments reveal that past acquisitions overpaid for assets with weaker demand than expected.
- Higher refinancing costs or near-term maturities redirect operating cash flow to creditors instead of product investment or debt reduction.
CLVT news
Loading headlines…
Financial statements
CLVT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
CLVT: quick answers
- When does Clarivate (CLVT) report earnings next?
- Clarivate's next results are projected for February 23, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
- What is CLVT's short interest?
- As of October 30, 2026, 48.4M CLVT shares were sold short, 7.57% of its shares outstanding, up 3.5% from the count before. At the stock's average daily volume that is 14 days to cover. FINRA publishes the count twice a month. CLVT short interest history
- Have members of Congress traded CLVT?
- 2 trades in CLVT have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed CLVT trade
